尖峯集團(600668.SH)：目前上海北卡已不持有“蒈醛酸內酯、卡龍酸、卡龍酸酐及其關鍵中間體的新合成方法”的生產專利
格隆匯12月29日丨尖峯集團(600668.SH)公佈關於股票交易異常波動的公吿，公司股票在2021年12月27日、2021年12月28日、2021年12月29日連續三個交易日內日收盤價格累計漲幅達到33.11%，累計偏離上證指數30.59%，累計偏離水泥行業指數27.91%，構成《上海證券交易所交易規則》規定的股票交易異常波動情形。敬請廣大投資者注意二級市場交易風險，理性決策，審慎投資。
經公司自查並向控股股東、實際控制人核實，除在指定媒體上已公開披露的信息外，不存在正在籌劃涉及公司的重大資產重組、股份發行、收購、債務重組、業務重組、資產剝離、資產注入、股份回購、股權激勵、破產重整、重大業務合作、引進戰略投資者等重大事項。
截止至公吿披露日，子公司上海北卡醫藥技術有限公司(上海北卡)及其子公司以農藥原藥及中間體為主要業務，中間體主要品種為左氧氟羧酸、氧氟羧酸，卡隆酸酐的銷售量較少，毛利率低，2021年度卡隆酸酐銷售收入約為1260.37萬元，約為公司2020年度銷售總收入的0.39%，銷售客户全部為國內客户，目前上海北卡已不持有“蒈醛酸內酯、卡龍酸、卡龍酸酐及其關鍵中間體的新合成方法”的生產專利(申請號：2011102478118)。
目前公司日常經營情況及外部環境未發生重大變化。公司的主營業務仍以水泥和醫藥為主，屬於非金屬礦物製品業，根據公司2021年前三季度的財務數據，公司建材行業營業收入佔比超5成。
公司近一年又一期的淨利潤和扣除非經常性損益的淨利潤均同比下滑。2020年，公司歸屬於上市公司股東的淨利潤為5.84億元，比2019年下降19.36%，歸屬於上市公司股東的扣除非經常性損益的淨利潤為5.19億元，比2019年下降16.65%；2021年前三季度，公司歸屬於上市公司股東的淨利潤4.24億元，比上年同期下降17.82%，歸屬於上市公司股東的扣除非經常性損益的淨利潤為4.12億元，比上年同期下降9.25%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
